RDY Total Stockholder Equity vs Current Deferred Revenue Analysis
| RDY Stock | USD 74.55 0.53 0.72% |
Dr Reddys financial indicator trend analysis is much more than just examining Dr Reddys Laboratories latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Dr Reddys Laboratories is a good investment. Please check the relationship between Dr Reddys Total Stockholder Equity and its Current Deferred Revenue accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Dr Reddys Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.
Total Stockholder Equity vs Current Deferred Revenue
Total Stockholder Equity vs Current Deferred Revenue Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Dr Reddys Laboratories Total Stockholder Equity account and Current Deferred Revenue. At this time, the significance of the direction appears to have almost no relationship.
The correlation between Dr Reddys' Total Stockholder Equity and Current Deferred Revenue is 0.1. Overlapping area represents the amount of variation of Total Stockholder Equity that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of Dr Reddys Laboratories, assuming nothing else is changed. The correlation between historical values of Dr Reddys' Total Stockholder Equity and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Stockholder Equity of Dr Reddys Laboratories are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Total Stockholder Equity i.e., Dr Reddys' Total Stockholder Equity and Current Deferred Revenue go up and down completely randomly.
Correlation Coefficient | 0.1 |
| Relationship Direction | Positive |
| Relationship Strength | Insignificant |
Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Current Deferred Revenue
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.Most indicators from Dr Reddys' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Dr Reddys Laboratories current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Dr Reddys Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. At this time, Dr Reddys' Tax Provision is fairly stable compared to the past year. Enterprise Value is likely to rise to about 740.6 B in 2024, whereas Selling General Administrative is likely to drop slightly above 39.7 B in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 113.8B | 203.0B | 233.4B | 245.1B | Total Revenue | 214.4B | 245.9B | 282.8B | 296.9B |
Dr Reddys fundamental ratios Correlations
Click cells to compare fundamentals
Dr Reddys Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Dr Reddys fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 232.2B | 265.5B | 296.7B | 322.9B | 371.3B | 206.1B | |
| Other Current Liab | 39.4B | 33.5B | 41.6B | 48.9B | 56.2B | 59.0B | |
| Total Current Liabilities | 72.8B | 81.5B | 97.8B | 85.7B | 98.6B | 68.3B | |
| Total Stockholder Equity | 155.0B | 175.0B | 190.5B | 232.9B | 267.8B | 281.2B | |
| Retained Earnings | 144.2B | 157.9B | 175.7B | 215.6B | 247.9B | 260.3B | |
| Accounts Payable | 10.7B | 21.9B | 25.6B | 22.7B | 26.1B | 15.0B | |
| Cash | 2.1B | 14.8B | 14.9B | 5.8B | 6.6B | 6.3B | |
| Other Assets | 14.8B | 11.6B | 13.7B | 7.1B | 8.2B | 8.6B | |
| Short Term Investments | 23.7B | 19.7B | 29.5B | 61.0B | 70.1B | 73.6B | |
| Inventory | 35.1B | 45.4B | 50.9B | 48.7B | 56.0B | 30.4B | |
| Total Liab | 77.3B | 90.5B | 106.1B | 90.0B | 103.5B | 88.4B | |
| Intangible Assets | 27.7B | 35.6B | 27.2B | 30.7B | 35.3B | 24.0B | |
| Property Plant Equipment | 52.3B | 57.1B | 62.2B | 66.3B | 76.2B | 80.1B | |
| Short Long Term Debt Total | 22.1B | 30.3B | 33.8B | 13.5B | 15.5B | 14.7B | |
| Other Liab | 3.5B | 3.1B | 2.7B | 2.5B | 2.9B | 3.1B | |
| Property Plant And Equipment Net | 52.3B | 57.1B | 62.2B | 56.5B | 65.0B | 54.0B | |
| Current Deferred Revenue | 1.9B | 2.0B | 2.6B | 2.0B | 1.8B | 1.7B | |
| Net Debt | 20.0B | 15.5B | 19.0B | 7.7B | 8.8B | 8.4B | |
| Non Current Assets Total | 101.9B | 117.2B | 115.5B | 118.6B | 136.4B | 95.9B | |
| Non Currrent Assets Other | 2.6B | 952M | 948M | 12.7B | 14.6B | 15.4B | |
| Cash And Short Term Investments | 25.7B | 34.6B | 44.4B | 66.7B | 76.8B | 80.6B | |
| Net Receivables | 61.8B | 52.4B | 70.0B | 72.5B | 83.4B | 46.9B | |
| Good Will | 4.0B | 4.6B | 4.4B | 5.5B | 6.3B | 6.6B | |
| Common Stock Shares Outstanding | 166.1M | 166.3M | 166.3M | 166.4M | 191.3M | 175.2M | |
| Liabilities And Stockholders Equity | 232.2B | 265.5B | 296.7B | 322.9B | 371.3B | 215.0B | |
| Non Current Liabilities Total | 4.4B | 9.0B | 8.3B | 4.3B | 4.9B | 4.7B | |
| Other Current Assets | 5.8B | 14.5B | 13.9B | 15.1B | 17.4B | 9.8B | |
| Other Stockholder Equity | 7.5B | 14.9B | 12.9B | 15.2B | 17.4B | 18.1B | |
| Total Current Assets | 130.4B | 148.2B | 181.1B | 204.3B | 234.9B | 120.7B | |
| Accumulated Other Comprehensive Income | 2.4B | 1.3B | 1.1B | 1.3B | 1.5B | 1.4B | |
| Short Term Debt | 20.8B | 24.0B | 28.1B | 12.2B | 14.0B | 27.5B | |
| Property Plant And Equipment Gross | 52.3B | 57.1B | 142.0B | 152.3B | 137.0B | 130.2B | |
| Net Tangible Assets | 91.9B | 123.3B | 134.8B | 158.9B | 182.7B | 102.9B | |
| Long Term Investments | 3.1B | 8.3B | 8.0B | 6.1B | 7.0B | 4.5B | |
| Short Long Term Debt | 20.3B | 24.0B | 28.1B | 12.2B | 11.0B | 17.2B | |
| Long Term Debt Total | 1.3B | 6.3B | 5.7B | 1.3B | 1.2B | 1.1B |
Currently Active Assets on Macroaxis
When determining whether Dr Reddys Laboratories offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dr Reddys' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dr Reddys Laboratories Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dr Reddys Laboratories Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Dr Reddys Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. Note that the Dr Reddys Laboratories information on this page should be used as a complementary analysis to other Dr Reddys' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Complementary Tools for RDY Stock analysis
When running Dr Reddys' price analysis, check to measure Dr Reddys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dr Reddys is operating at the current time. Most of Dr Reddys' value examination focuses on studying past and present price action to predict the probability of Dr Reddys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dr Reddys' price. Additionally, you may evaluate how the addition of Dr Reddys to your portfolios can decrease your overall portfolio volatility.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |
Is Dr Reddys' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dr Reddys. If investors know RDY will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dr Reddys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.103 | Dividend Share 40 | Earnings Share 3.76 | Revenue Per Share 272.4618 | Quarterly Revenue Growth 0.066 |
The market value of Dr Reddys Laboratories is measured differently than its book value, which is the value of RDY that is recorded on the company's balance sheet. Investors also form their own opinion of Dr Reddys' value that differs from its market value or its book value, called intrinsic value, which is Dr Reddys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dr Reddys' market value can be influenced by many factors that don't directly affect Dr Reddys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dr Reddys' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dr Reddys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dr Reddys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.